Wednesday, March 6, 2024 Long-Acting HIV Treatment Benefits Adults with Barriers to Daily Pill Taking and Adolescents with Suppressed HIV Colorized transmission electron micrograph of two HIV-1 virus particles (red/yellow) budding from the plasma membrane of an H9 T cell (teal). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID Long-acting, injectable antiretroviral therapy (ART) with cabotegravir and rilpivirine suppressed HIV replication better than oral ART in people who had previously experienced challenges taking daily oral regimens and was found safe in adolescents with HIV viral suppression, according to two NIAID-sponsored studies presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). These studies provide evidence on the drug regimen in populations for whom limited data exist.  National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107